drugset
drugset / Trial / NCT06546449

LH-001 vs Placebo in Healthy Participants

NCT06546449 ↗

Phase 1 Recruiting 56 enrolled Chien-Liang Lin National Institute on Aging (NIA) · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this clinical trial is to evaluate the safety and tolerability of LH-001 when administered as an oral, single or multiple dose(s) at ascending dose levels in healthy participants.

Timeline

Start
2025-05-05
Primary completion
2027-06
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LH-001 Unknown 12.5 mg Oral
Subject LH-001 Unknown 25 mg Oral
Subject LH-001 Unknown 50 mg Oral
Subject LH-001 Unknown 100 mg Oral

Indications

No indication recorded.